Table 3.
Results of multivariable Cox proportional hazards model for all-cause post-LT mortality and graft failure
| Post-LT mortality N=1,129 |
Graft failure N=1,128* |
|||
|---|---|---|---|---|
|
| ||||
| Variable | HR (95% CI) | p value | HR (95% CI) | p value |
| ALF etiology† | 0.087 | 0.134 | ||
| APAP | --- | --- | ||
| HBV | 0.84(0.57–1.24) | 0.89(0.63–1.26) | ||
| AIH | 0.59(0.39–0.89) | 0.66(0.46–0.94) | ||
| DILI | 0.75(0.51–1.11) | 0.89(0.63–1.24) | ||
| Female | 0.82(0.62–1.08) | 0.162 | 0.90(0.70–1.15) | 0.392 |
| Age (years), N (%) | <0.001 | 0.083 | ||
| ≤40 | --- | --- | ||
| 40–59 | 0.96(0.73–1.27) | 0.86(0.68–1.10) | ||
| ≥60 | 1.81(1.22–2.70) | 1.31(0.90–1.90) | ||
| Race/ethnicity | <0.001 | <0.001 | ||
| White | --- | --- | ||
| Black | 1.69(1.23–2.30) | 1.77(1.34–2.33) | ||
| Hispanic | 0.91(0.57–1.44) | 0.97(0.65–1.46) | ||
| Asian | 0.44(0.23–0.83) | 0.58(0.34–0.99) | ||
| Other | 1.11(0.35–3.49) | 1.43(0.59–3.50) | ||
| MELD, per point | 1.00(0.98–1.02) | 0.959 | 1.00(0.98–1.01) | 0.810 |
| Clinical Factors at WL | ||||
| Grade 3–4 encephalopathy | 0.98(0.72–1.32) | 0.884 | 0.93(0.71–1.21) | 0.575 |
| Ascites present | 1.38(1.06–1.79) | 0.016 | 1.39(1.10–1.75) | 0.005 |
| Mechanical ventilation | 1.34(1.00–1.78) | 0.046 | 1.27(0.99–1.64) | 0.060 |
| Dialysis | 0.78(0.56–1.10) | 0.159 | 0.87(0.65–1.18) | 0.378 |
| Donor Age (per 10 years) | 1.16(1.08–1.25) | <0.001 | 1.18(1.10–1.25) | <0.001 |
| Cold Ischemia Time (per hour) | 1.01(0.97–1.04) | 0.731 | 1.01(0.99–1.04) | 0.319 |
| DCD Liver | 1.54(0.76–3.15) | 0.231 | 2.06(1.18–3.62) | 0.012 |
| Era | 0.984 | 0.659 | ||
| 2002–2007 | --- | --- | ||
| 2008–2013 | 1.00(0.75–1.34) | 0.87(0.69–1.11) | ||
| 2014–2019 | 1.04(0.70–1.54) | 0.78(0.56–1.09) | ||
Abbreviations: LT – liver transplant; OR – Odds ratio; ALF – acute liver failure; APAP – acetaminophen; DILI – drug induced liver injury; AIH – autoimmune hepatitis; HBV – hepatitis B virus; MELD – Model for End-Stage Liver Disease; WL – waitlist
Notes:
The number of transplanted ALF patients in the study population included N=436 APAP, N=278 HBV, N=271 AIH and N=232 other DILI. Additional demographic and clinical characteristics of transplanted ALF patients are shown in Supplemental Table 5.
*
Sample sizes differ due to number of patients experiencing the failure events of death and death/retransplant at t=0 (N=18 and N=19 respectively).